Overview

Orexa is a phase 2 pharmaceutical company that develops and commercializes therapeutics to increase food intake. Its lead compound ORE-001 is a proprietary oral formulation, based on a well known anesthetic. The company has started its first phase 2a study in the Prevention of Post-Operative Ileus. Furthermore it is in preparation for phase 2a studies in Anorexia and Cachexia. With these three indications increased food intake could lead to an improved patient health, a shorter hospital stay and significant cost savings. Orexa was founded in 2016 and is headquartered in Herpen (Oss Region, Noord Brabant), The Netherlands. Attractive risk/reward: • Lower risk, because the active substance is already well known for many decades; • Lean and fast development plan; • Very attractive market potential. Strong patent portfolio: • Broad claims for all local anesthetics to increase food intake after both single and repeated administration; • Well understood mode of action; • Novel mode of delivery, with a proprietary oral formulation. We are looking for partnerships with: ★ an experienced mid or big pharma company with a focus on 505(b)(2) applications for the late stage clinical development and for the marketing in the US & EU markets (and possibly more); ★ a suitable Chinese company with experience in phase 2 & phase 3 clinical trials and an effective sales channel in the majority of the Chinese market; ★ a large scale specialized animal food company or a large veterinary drug company for the veterinary applications. We’d love to hear from you. We’ll get back to you as soon as we can! You can contact us at info@orexa.nl.